OTTAWA, ONTARIO / February 28, 2014 / ACCESSWIRE
/ Avivagen Inc. (TSXV:VIV), a wellness company
developing and delivering products that support and enhance the
health and quality of life for animals and the people who care for
them, announces the nomination of a new Director, Mr. G.F. Kym
Anthony, and the retirement of its current Chairman, Mr. Jacques
Brault.
Mr. G.F. Kym (Kym) Anthony has considerable experience in life
sciences, agriculture, capital markets and corporate governance. He
is currently independent Chairman of the Board of Prometic Life
Sciences Inc. (PLI - TSX), Board Vice-Chairman of COM DEV
International (CDV - TSX), Executive Chairman of Hybrid Partners
and a Proprietor of Top Meadow Farms. Previously, Mr. Anthony has
served as President or CEO of several major Canadian investment
dealers, Chairman of the Investment Dealer's Association of Canada
(IDA) and Executive Chairman of Broadacre Agriculture.
Should his nomination be confirmed by Avivagen's
shareholders at the upcoming annual general meeting to be held on
April 4, 2014, Mr. Anthony has also agreed to serve as independent
Chairman of the Board and he has the support of Avivagen's other
Directors for that position. Should he be elected to the board, Mr.
Anthony has indicated that it is his intention to make a direct
investment in the Company of $100,000. The terms of this proposed
private placement are expected to be the same as Avivagen's
November, 2013 financing: a sale of units priced at $0.07, with
each unit being comprised of one common share and
one-half of a common share purchase warrant. Each whole warrant
will entitle the holder to acquire one common share of Avivagen at
an additional purchase price of $0.12 for three years from
closing. Avivagen's CEO, Cameron Groome, CFO, Chris
Boland, Director of Product Development and Quality Assurance,
Janusz Daroszewski, and retiring Chairman, Jacques Brault, also
propose to make further investments on these terms: in amounts of
$17,500, $17,500, $17,500 and $20,000 respectively.
Kym Anthony spoke about his decision to join the Avivagen Board,
"Raising livestock and improving the standards of their care have
been two of my longtime passions. The combination of the business
opportunities in the livestock field being joined to strong
technologies and management make Avivagen an exciting growth
company. I look forward to working with the Board and management to
help realize the Company's full potential."
Jacques Brault remarked on his decision to not stand for
re-election. "There comes a time when you decide to
retire and wind down your business activities. I am therefore not
standing for re-election to the Avivagen Board. In departing, I am
proud of Avivagen's progress towards profitability and that we have
attracted such a qualified candidate to serve as the new
independent Chairman of the Board."
Cameron Groome, C.E.O. and President of Avivagen also
commented "We are very pleased to have a person with Kym's
experience and abilities agree to join our Board. Once our
shareholders have spoken, I welcome the opportunity to work closely
with Kym and our other Directors to perfect our strategies and
implement them effectively. I also want to thank Jacques Brault for
his many contributions to our Company and wish him a very happy
retirement."
Mr. Anthony's election to the Avivagen board of directors
remains subject to shareholder and TSX Venture Exchange approvals.
The proposed private placement of units remains subject to TSX
Venture Exchange approval.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company
trading on the TSX Venture Exchange under the ticker symbol "VIV".
The Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of
the National Research Council of Canada (NRC) - in Ottawa, Ontario
and Charlottetown, Prince Edward Island. More
information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research results indicate OxC-beta supports innate immune
function, which can help maintain good health. In pets, OxC-beta
supports overall vitality and energy, mobility and joint function,
skin, coat and gut. Results observed in food animals have included
healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for
livestock, Vivamune(TM) Health Chews and Oximunol(TM)
Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold
in 1.0 or 5.0 Kg quantities for parts-per-million addition to
animal feeds, in accordance with producer-developed protocols. In
past studies, OxC-beta has been shown to support health and growth
in species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews
- For dogs and cats
Vivamune(TM) Health Chews, containing Avivagen's
proprietary active ingredients, are scientifically-formulated chews
for dogs and cats. Vivamune(TM) Health Chews work with a pet's own
immune system to maintain overall health and well-being. They are
sold in re-sealable packages of 30 chews and are currently
available in the United States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM) Chewables -
For dogs
Oximunol(TM) Chewables are scientifically-formulated
chewable tablets that contain Avivagen's proprietary, patented
active ingredient OxC-beta. OxC-beta has been shown to stimulate
innate cellular immunity and may thereby help to maintain overall
health and well-being. Oximunol(TM) Chewables are distributed by
Bayer Healthcare LLC and are available through veterinarians for
dogs of all ages in the United States.
Forward Looking
Statements
This news release
includes certain forward-looking statements that are based upon
current expectations, which involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment
in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions
"will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", and similar expressions. The forward-looking statements
reflect the current expectations of Avivagen Inc. regarding future
results or events. These forward-looking statements are subject to
a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
